Dr.  

Kim A. Papp

, Canada


Presentations

Adverse events from biologic therapy 12 October 2019 15:40 - 16:00
Therapeutic pipeline 12 October 2019 16:00 - 16:20
Long-term Efficacy and Safety of Continuous Q12W Risankizumab: Results from the Open-Label Extension LIMMitless 10 October 2019 08:30 - 08:40
Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate-to-severe plaque psoriasis: 60-week results from a randomised, double-blinded, Phase 2b extension study 10 October 2019 10:25 - 10:35
Analysis of Patients With Moderate Psoriasis in "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) 09 October 2019 00:00 - 00:00
Patient-Related Outcomes in the "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Population 09 October 2019 00:00 - 00:00
Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis 12 October 2019 08:45 - 09:00

Abstracts

Analysis of Patients With Moderate Psoriasis in "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Psoriasis More
Patient-Related Outcomes in the "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Population Psoriasis More
Efficacy and Safety of Risankizumab in Patients With Active Psoriatic Arthritis Over 24 Weeks: Clinical and Biomarker Results From a Phase 2 Trial Biologics, Immunotherapy, Molecularly Targeted Therapy More